BPC-157 Research Overview: Sequence, Study Models and Lot Records

BPC-157 has an unusual record. The number of animal papers is large, but most of them come from one research group, and human data is close to absent. This profile stays with the laboratory record. For any individual batch, the analytical side lives in the LIV More Lot Passport, where each lot’s purity, amount, test date and certificate are filed against the lot number printed on the vial.

It is the first compound profile in the LIV More Journal, and later profiles follow the same pattern in the Journal archive.

Every finding below is labeled by study type, and no study amounts are restated.

What the BPC-157 peptide is

BPC-157 is a linear peptide of 15 residues: glycine, glutamic acid, three prolines, glycine, lysine, proline, alanine, two aspartic acids, alanine, glycine, leucine and valine. Its PubChem record gives the molecular formula C62H98N16O22 and a molecular weight of 1419.5. The sequence contains no cysteine, methionine or tryptophan, so it has no disulfide bonds to form and none of the residues most prone to oxidation.

The name comes from the Zagreb research group that has published much of the record, where it is called a “stable gastric pentadecapeptide”. A 2020 review from that group describes it as continuously present in the gastric mucosa and gastric juice. Early papers also refer to it by development codes, including PL 14736 and PLD-116.

These distinctions have practical weight. Two vials both labeled BPC-157 can differ in counterion and peptide content while showing the same purity, and each difference changes what the analytical values should be.

Where the BPC-157 record comes from

The literature is large for a peptide with no approved use, but it is concentrated. A large share of the in vivo work, and many of the review articles that summarize it, were written by one group at the Department of Pharmacology, University of Zagreb. Independent laboratories, notably a group at Chang Gung University in Taiwan, have added mechanism work in cultured cells and rodent models.

A 2025 systematic review in HSS Journal searched PubMed, Cochrane and Embase up to June 2024 for musculoskeletal and safety literature. Of 36 included studies, 35 were preclinical and 1 was clinical, and the authors reported finding no clinical safety data.

For analysts, the working point is that the size of the BPC-157 literature says more about the attention it has drawn than about the strength of its evidence.

What published BPC-157 research examines

Most of the record falls into a few study types. Each item below names the model and what was measured.

• Animal model, tendon transection. Staresinic and colleagues transected the Achilles tendon in rats and compared BPC-157 with saline controls over two weeks. They measured load of failure, Young’s modulus, a functional index, tissue histology and defect size. The same paper included a cultured tendocyte experiment with 4-hydroxynonenal as a growth inhibitor.
• Cell culture, tendon fibroblasts. Chang and colleagues studied explants and fibroblasts from rat Achilles tendon. They measured explant outgrowth, proliferation by MTT assay, survival under hydrogen peroxide stress, transwell migration, cell spreading, F-actin formation and phosphorylation of FAK and paxillin. Proliferation was not directly affected. The other measures changed in a dose dependent way.
• Cell culture, gene expression. In a follow up study, the same group ran a cDNA microarray on treated rat tendon fibroblasts. They identified growth hormone receptor as one of the most up-regulated genes, then measured its mRNA and protein levels, cell proliferation with added growth hormone, and Janus kinase 2 activation.
• Angiogenesis, three models. Hsieh and colleagues used a chick chorioallantoic membrane assay, endothelial tube formation in human vascular endothelial cells and a rat hind limb ischemia model. They measured vessel density, blood flow recovery by laser Doppler, VEGFR2 expression and internalization, and VEGFR2, Akt and eNOS signaling.

These studies share a pattern. Each measures tissue or molecular markers under controlled laboratory conditions. None of them measures an outcome in a person, and the conclusions belong to the authors of each paper.

What the BPC-157 literature does not establish

The gaps are larger than the findings. Across the papers cited here, the evidence comes from rodent injury models, cultured cells and an avian membrane assay.

• No established human findings. The human literature consists of a retrospective chart review with telephone follow up and no control group, and a two participant pilot report. Neither design can establish an effect or a safety profile.
• Replication is limited. Much of the in vivo work comes from one group. Independent confirmation exists for some mechanisms in cultured cells, but not for most of the animal outcomes.
• Mechanism is not outcome. Changes in FAK phosphorylation, VEGFR2 signaling or receptor expression describe cell behavior in a dish. They do not predict what happens in a whole organism.
• Model markers are not endpoints. Tendon load of failure in a rat and vessel density in a chick membrane are laboratory measurements. They are not clinical endpoints.
• No approved use. BPC-157 holds no FDA approval for any human or veterinary use, and nothing in this profile evaluates any claim of that kind.

Regulatory context shapes how any of this can be written. The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding. It cites possible immunogenicity, complexities with peptide-related impurities and active ingredient characterization, and limited safety information. Under 21 CFR 201.128, intended use is judged by the objective intent of the people responsible for an article, as shown through labeling claims, advertising and the circumstances of distribution. The Journal therefore describes study designs and measurements and stops there.

Reading a certificate for a BPC-157 lot

A certificate of analysis is the document that ties a physical vial to analytical data. For a 15-residue peptide, two numbers get confused more often than any others: purity and peptide content.

HPLC purity is the first check. It reports the main peak’s share of the UV-absorbing material, and it should come with the chromatogram for the same lot. It does not measure water or counterion, so a lot can read high purity while its peptide content by weight is lower. Identity by mass is the second check. A peptide this size often appears in electrospray spectra as a multiply charged ion, so the certificate should say which ion was read and which form the expected mass refers to. Appearance is the third. A lyophilized peptide should be described as a dry solid consistent with the product record.

• Lot number on the certificate matches the vial label
• Stated form names the peptide and any counterion
• Observed mass agrees with the expected mass for that stated form, with the ion named
• HPLC result and chromatogram are attached for the same lot
• Peptide content, if reported, is kept separate from HPLC purity
• Stated amount per vial matches the label
• Testing laboratory and test date are identified

The research use policy and the terms of sale set out the only terms on which LIV MORE LLC supplies research material. Storage and delivery are covered on the shipping and returns page, and recurring documentation questions are answered in the site FAQ.

To see how these fields appear on a real document, open the BPC-157 entry in the Lot Passport and check each item above against the record for that batch.

Frequently asked questions